In a significant advancement for cancer care in the UK, NHS England has launched a new injectable formulation of Keytruda, a leading immunotherapy drug. This innovative delivery method promises to drastically reduce the time patients spend in hospital, potentially transforming the treatment landscape for thousands of individuals battling various forms of cancer.
A Revolutionary Approach to Cancer Treatment
Keytruda, generically known as pembrolizumab, has been a cornerstone in the treatment of numerous cancers since its introduction in 2015. Traditionally administered via intravenous infusion, the therapy typically required over an hour of hospital time for each treatment session. However, the newly approved injectable version can be administered in mere minutes, allowing for a more efficient and patient-friendly experience.
Shirley Xerxes, an 86-year-old patient from St Albans, was among the first to receive this new formulation at the Mount Vernon Cancer Centre. Reflecting on her experience, she noted, “I was in the chair for a matter of minutes instead of an hour or more. It’s made such a difference and gives me more time to live my life, including spending more time gardening.” This sentiment underscores the profound impact that streamlined treatment can have on patients’ quality of life.
Expanding Access and Convenience
Each year, approximately 14,000 patients in England begin a course of Keytruda. With the introduction of the injectable form, a large proportion of these individuals are expected to transition to this more efficient treatment option. Depending on the specific cancer diagnosis, the injectable Keytruda will be administered every three weeks as a one-minute injection, or every six weeks as a two-minute injection.
The shift to this method is not only about convenience for patients; it also aims to alleviate pressure on NHS facilities. Professor Peter Johnson, the national clinical director for cancer at NHS England, highlighted the benefits of this change, stating, “If we can do this in a much shorter period of time, it frees up space in our chemotherapy units and means we can start thinking about giving treatment in the community and away from hospitals.”
This strategic move could lead to more flexible treatment options, allowing patients to receive care in locations closer to home, thus reducing the burden of travel and waiting times.
The Science Behind Immunotherapy
Immunotherapy represents a groundbreaking shift in cancer treatment. It works by enabling the body’s immune system to identify and combat cancer cells that often evade detection. This mechanism can be likened to removing an “invisibility cloak” that cancer cells use to hide from immune responses. The development of immunotherapy has garnered significant recognition, culminating in the Nobel Prize for Medicine awarded in 2018 to scientists James Allison and Tasuku Honjo for their pioneering work in this field.
Keytruda has been at the forefront of this revolution, initially approved for treating skin cancer and later expanded to address 14 different types of cancer, including lung, cervical, and breast cancers.
Financial Implications and Future Considerations
While NHS England has yet to disclose the financial terms of its agreement with Merck Sharp & Dohme (MSD), it is believed that the cost associated with the injectable version will be comparable to the existing infusion method. Keytruda has already achieved remarkable financial success, with sales reaching an estimated $180 billion since its launch over a decade ago.
However, the impending expiration of patents protecting the original drug in the coming years raises questions about the future market landscape. Critics, including US Senator Elizabeth Warren, have voiced concerns that the introduction of the new injectable form may be a strategy by MSD to extend its market exclusivity by applying for different patents. MSD, in response, maintains that this new formulation brings “meaningful benefits” to healthcare providers by reducing administration time and optimising clinical resources.
Why it Matters
The introduction of the injectable Keytruda represents a pivotal moment in the fight against cancer, not only enhancing patient experience but also potentially reshaping treatment protocols within the NHS. As the healthcare system grapples with increasing demands, innovations like this can help streamline processes, reduce strain on resources, and ultimately improve patient outcomes. This development is not merely a change in administration; it signals a significant shift towards more efficient, patient-centred cancer care, with the potential to make a lasting impact on the lives of thousands.
